(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Palvella Therapeutics's earnings in 2025 is -$35,066,000.On average, 14 Wall Street analysts forecast PVLA's earnings for 2025 to be -$42,146,190, with the lowest PVLA earnings forecast at -$42,223,127, and the highest PVLA earnings forecast at -$35,296,413. On average, 14 Wall Street analysts forecast PVLA's earnings for 2026 to be -$46,240,432, with the lowest PVLA earnings forecast at -$57,070,820, and the highest PVLA earnings forecast at -$35,420,696.
In 2027, PVLA is forecast to generate -$73,780,393 in earnings, with the lowest earnings forecast at -$116,693,588 and the highest earnings forecast at -$37,284,944.